Publication details
Antikoagulační léčba 2018
| Title in English | Anticoagulation therapy 2018 |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Intervenční a akutní kardiologie |
| MU Faculty or unit | |
| Citation | |
| web | https://www.iakardiologie.cz/artkey/kar-201802-0013_Antikoagulacni_lecba_2018.php |
| Keywords | hypercoagulable states; novel antithrombotics; fondaparinux; idraparinux; dabigatran; rivaroxaban; apixaban; edoxaban |
| Description | Hypercoagulable states are among the most frequent causes of morbidity and mortality in the developed countries. Hemostasisplays an important role not only in the stopping of bleeding, but is also involved in immunity, wound healing, and the processesof growth, progression, and metastasizing of malignant tumors. This is the reason why many research teams pay great attention tothe issue of hemostasis, including the development of new antithrombotic drugs. Hemostasis is being explored in detail on manylevels, this creating a basis for the development and testing of new drugs in both preclinical and clinical trials. At present, pentasacharides,direct inhibitors of factor Xa, and direct trombin inhibitors are the most promising drugs. These new antithromboticscan be expected to replace the classic drugs (heparins and vitamin K antagonists) in the prevention and treatment of thrombosisin both the venous and arterial circulations. |